The global prevalence of brain disorders leading to cognitive decline will increase significantly in the future but new treatments and management approaches are available for certain conditions. There has never been a more important time develop novel technologies for the early assessment and monitoring of cognitive function.
As new treatments for neurodegenerative disorders are developed it will be critical to identify novel biomarkers of safety and efficacy. Digital biomarkers are an important potential tool in clinical trials for assessing medicines safety or efficacy due to their non-invasive nature, ability to deploy widely and remotely, and relative low cost.
Silicon Neural aims to develop novel digital biomarkers of spatial cognition that can be validated and used in clinical practice, either alone or in combination with other approaches.
